Physician profile
Aamir Raza
NPI 1578710158
$2,721.66
in general payments reported to CMS, 2019-2025
22 companies · $1,498 in 2025
The $1,498 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.43 · 2023: $446 · 2024: $765 · 2025: $1,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,530 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,530.24 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $868.70 | 2023-2025 | Acthar, Amitiza |
| Veloxis Pharmaceuticals, INC. | $361.54 | 2023-2025 | Envarsus |
| Takeda Pharmaceuticals U.S.A., INC. | $280.82 | 2023-2025 | Livtencity |
| Amgen INC. | $192.05 | 2024-2025 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $181.33 | 2023-2025 | Ultomiris |
| Apellis Pharmaceuticals, INC. | $115.41 | 2025 | |
| Novo Nordisk INC | $109.67 | 2023 | Wegovy |
| Galderma Laboratories, L.P. | $109.31 | 2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $103.67 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $89.91 | 2024-2025 | Lokelma |
| One Lambda, INC. | $49.87 | 2024 | |
| Organ Recovery Systems, INC. | $39.69 | 2025 | |
| Kaneka Medical America LLC | $30.43 | 2024 | |
| Travere Therapeutics, INC. | $27.17 | 2025 | |
| Ani Pharmaceuticals, INC. | $26.03 | 2023 | Purified Cortrophin Gel |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $24.97 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.22 | 2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $21.41 | 2023 | Prevymis |
| Aurinia Pharma U.S., INC. | $21.11 | 2024 | Lupkynis |
| Calliditas Therapeutics US INC. | $16.73 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $15.19 | 2024 | Nulojix |
| Renalytix Ai, INC. | $12.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aamir Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.